Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLRNASDAQ:EVOKNASDAQ:KZIANASDAQ:NEPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLRAllarity Therapeutics$1.00+2.1%$0.98$0.61▼$7.45$15.08M-0.151.13 million shs294,547 shsEVOKEvoke Pharma$2.63-0.4%$3.04$1.94▼$14.00$3.92M0.04124,633 shs9,949 shsKZIANovogen$6.34-2.9%$4.96$2.86▼$79.00$6.40M2.48384,343 shs60,192 shsNEPTNeptune Wellness Solutions$0.39$0.19▼$28.00$906K2.19462,687 shs2.25 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLRAllarity Therapeutics0.00%+7.52%+18.33%+6.37%-84.34%EVOKEvoke Pharma0.00%-2.05%-21.63%-4.36%-58.57%KZIANovogen0.00%-30.71%+67.72%+61.96%-44.53%NEPTNeptune Wellness Solutions0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALLRAllarity Therapeutics0.7971 of 5 stars0.04.00.00.01.40.01.3EVOKEvoke Pharma1.1883 of 5 stars0.05.00.00.02.90.00.6KZIANovogen3.0046 of 5 stars3.52.00.00.03.30.00.0NEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLRAllarity Therapeutics 0.00N/AN/AN/AEVOKEvoke Pharma 0.00N/AN/AN/AKZIANovogen 3.00Buy$57.50806.94% UpsideNEPTNeptune Wellness Solutions 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NEPT, KZIA, ALLR, and EVOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLRAllarity TherapeuticsN/AN/AN/AN/A$1.62 per shareN/AEVOKEvoke Pharma$10.25M0.38N/AN/A$4.74 per share0.55KZIANovogen$1.51M4.24N/AN/A($9.87) per share-0.64NEPTNeptune Wellness Solutions$52.62M0.00N/AN/A($91.90) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLRAllarity Therapeutics-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)EVOKEvoke Pharma-$5.35M-$2.87N/A∞N/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)KZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/ANEPTNeptune Wellness Solutions-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/ALatest NEPT, KZIA, ALLR, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ALLRAllarity Therapeutics-$8.10-$0.25+$7.85-$0.25N/AN/A5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLRAllarity TherapeuticsN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ANEPTNeptune Wellness SolutionsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLRAllarity TherapeuticsN/A2.662.66EVOKEvoke PharmaN/A1.551.50KZIANovogenN/A0.21N/ANEPTNeptune Wellness SolutionsN/A0.230.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLRAllarity Therapeutics11.53%EVOKEvoke PharmaN/AKZIANovogen30.89%NEPTNeptune Wellness Solutions14.44%Insider OwnershipCompanyInsider OwnershipALLRAllarity Therapeutics0.01%EVOKEvoke Pharma6.10%KZIANovogen1.00%NEPTNeptune Wellness Solutions5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLRAllarity Therapeutics1015.08 million15.08 millionNot OptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableKZIANovogen121.01 million997,000OptionableNEPTNeptune Wellness Solutions584.53 million4.30 millionNot OptionableNEPT, KZIA, ALLR, and EVOK HeadlinesRecent News About These Companiest20 world cup 2020 teamsDecember 28, 2024 | bweducation.businessworld.inBNeptune Wellness Solutions Inc. (NEPTF)November 27, 2024 | finance.yahoo.comThree Breakthrough Strategies To Revolutionize Pain Relief And WellnessNovember 7, 2024 | forbes.comThe Aesthetic Experience introduces AE WellnessNovember 7, 2024 | koin.comKNeptune homeless camp down to 13 people as deadline to shut it down is nearly hereOctober 18, 2024 | app.comAThe Next Era of Lenovo Neptune Water Cooling Arrives to Efficiently Power NVIDIA Blackwell Platform and AI at Every ScaleOctober 15, 2024 | valdostadailytimes.comVOpen Letter to Dominican President Luis Abinader: Stop Deportations Now!October 12, 2024 | counterpunch.orgC2024 Wellness Olympia Results & Prize Money — Isabelle Nunes Wins 1st TitleOctober 12, 2024 | fitnessvolt.comFKroger Wellness Festival canceled, products will go to people impacted by HeleneSeptember 28, 2024 | local12.comLRestore Hyper Wellness and MECOTEC Announce Strategic Partnership in Cryotherapy SolutionsSeptember 24, 2024 | tmcnet.comCapitol Wellness Solutions opens new medical marijuana dispensary in Baton RougeSeptember 21, 2024 | yahoo.comCapitol Wellness Solutions opened a new medical marijuana dispensary, for the first time in LouisianaSeptember 21, 2024 | msn.comGiant space balloon ‘Spaceship Neptune-Excelsior’ completes 2nd test flight in TitusvilleSeptember 19, 2024 | clickorlando.comCSpace Perspective's Spaceship Neptune capsule lifts off from ship on test flightSeptember 16, 2024 | floridatoday.comFNeptune Beach, FL Weather ConditionsAugust 30, 2024 | wunderground.comWHigh-tech wizardry and old-fashioned care will grow pot indoors at Neptune's GardenAugust 30, 2024 | app.comAYour Daily Horoscope: Sunday, August 25, 2024August 25, 2024 | msn.comExploring Alternative Wellness Options for Stress Management & RelaxationAugust 25, 2024 | spacecoastdaily.comSSunrise Total Mind Wellness closing its doors in New BraunfelsAugust 18, 2024 | herald-zeitung.comHNeptune Medical raises $97M for surgical robotics, spins out Jupiter EndovascularAugust 16, 2024 | therobotreport.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNEPT, KZIA, ALLR, and EVOK Company DescriptionsAllarity Therapeutics NASDAQ:ALLR$1.00 +0.02 (+2.12%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.00 +0.00 (+0.01%) As of 05:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.Evoke Pharma NASDAQ:EVOK$2.63 -0.01 (-0.38%) Closing price 06/27/2025 03:53 PM EasternExtended Trading$14.00 +11.37 (+432.32%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Novogen NASDAQ:KZIA$6.34 -0.19 (-2.91%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$6.23 -0.11 (-1.74%) As of 06:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Neptune Wellness Solutions NASDAQ:NEPTNeptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
